CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has launched Alnylam Assist™, a program dedicated to providing support to patients, families, and caregivers. Alnylam is committed to developing RNAi therapeutics for a number of genetic diseases and intends to implement certain aspects of Alnylam Assist broadly across its pipeline of novel investigational therapies in development.
Help employers find you! Check out all the jobs and post your resume.
